Carvedilol Suppresses Apoptosis and Ion Channel Remodelling of HL-1 Cardiac Myocytes Expressing E334K cMyBPC

Abstract Background: Besides its antiarrhythmic action, carvedilol has an activity to suppress cardiac tissue damage. However, it is unknown whether it has any effect on cellular apoptosis and ion channel remodelling. Purpose: To know whether carvedilol has any effect on apoptosis and ion channel remodeling of HL-1 cells expressing E334K MyBPC, and comparing it with bisoprolol. Method: We examined effects of carvedilol and bisoprolol on the levels of pro- and anti-apoptotic proteins and ion channels as well as apoptosis of HL-1 cells transfected with E334K MyBPC using Western blot and flow cytometry. Results: Carvedilol decreased the protein levels of p53, Bax and cytochrome c and increased that of Bcl-2 in HL-1 cells expressing E334K MyBPC. Bisoprolol failed to affect the protein levels. Both carvedilol and bisoprolol increased the protein levels of Cav1.2 but not that of Nav1.5. Carvedilol was stronger than bisoprolol at decreasing the number of annexin-V positive cells in HL-1 cells expressing E334K MyBPC. Conclusion: Carvedilol suppressed apoptosis of HL-1 cells expressing E334K MyBPC through modification of pro- and anti-apoptotic proteins, whose was associated with an increase of Cav 1.2 protein expression.

[1]  S. Niwano,et al.  Effect of carvedilol on atrial remodeling in canine model of atrial fibrillation. , 2014, Cardiovascular diagnosis and therapy.

[2]  I. Hisatome,et al.  Simultaneous Treatment with Azelnidipine and Olmesartan Inhibits Apoptosis of Hl-1 Cardiac Myocytes Expressing E334k cMyBPC , 2013, Drug Research.

[3]  C. Yeh,et al.  Carvedilol Treatment After Myocardial Infarct Decreases Cardiomyocytic Apoptosis in the Peri-infarct Zone During Cardioplegia-Induced Cardiac Arrest , 2013, Shock.

[4]  S. Matsuoka,et al.  Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. , 2011, Journal of molecular biology.

[5]  N. Dhalla,et al.  Mechanisms of the beneficial effects of beta-adrenoceptor antagonists in congestive heart failure. , 2010, Experimental and clinical cardiology.

[6]  I. Hisatome,et al.  Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. , 2008, Journal of molecular biology.

[7]  L. Xiaochun,et al.  Effects of carvedilol on cardiomyocyte apoptosis and gene expressionin vivo after ischemia-reperfusion in rats , 2008, Journal of Huazhong University of Science and Technology [Medical Sciences].

[8]  X. Chen,et al.  [Beneficial effects of carvedilol on cardiomyocyte apoptosis and bcl-2/bax expression after acute myocardial infarction an experiment with rats]. , 2006, Zhonghua yi xue za zhi.

[9]  C. Ko,et al.  A meta-analysis of perioperative beta blockade: what is the actual risk reduction? , 2005, Surgery.

[10]  Hong Jiang,et al.  The beta-adrenergic blocker carvedilol restores L-type calcium current in a myocardial infarction model of rabbit. , 2005, Chinese medical journal.

[11]  J. McMurray,et al.  Antiarrhythmic effect of carvedilol after acute myocardial infarction: results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. , 2005, Journal of the American College of Cardiology.

[12]  W. Claycomb,et al.  Cardiac physiology at the cellular level: use of cultured HL-1 cardiomyocytes for studies of cardiac muscle cell structure and function. , 2004, American journal of physiology. Heart and circulatory physiology.

[13]  K. Schulze-Osthoff,et al.  Effects of nebivolol on proliferation and apoptosis of human coronary artery smooth muscle and endothelial cells. , 2001, Cardiovascular research.

[14]  A. Zeiher,et al.  Congestive heart failure induces endothelial cell apoptosis: protective role of carvedilol. , 2000, Journal of the American College of Cardiology.

[15]  S. Sasayama,et al.  alpha- and beta-adrenergic pathways differentially regulate cell type-specific apoptosis in rat cardiac myocytes. , 1999, Circulation.

[16]  T. Yue,et al.  SB 211475, a metabolite of carvedilol, a novel antihypertensive agent, is a potent antioxidant. , 1994, European journal of pharmacology.

[17]  Hung‐Yuan Cheng,et al.  Carvedilol, a new vasodilator and beta adrenoceptor antagonist, is an antioxidant and free radical scavenger. , 1992, The Journal of pharmacology and experimental therapeutics.